ClinicalTrials.gg
CompletedNCT02547922TULIP-LN1Updated Nov 24, 2021Results posted

Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis

A Phase 2 interventional study of Anifrolumab and Placebo in Lupus Nephritis, sponsored by AstraZeneca. Completed at 80 sites in 17 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-11-24.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Enrollment
24th of 100
147 · median 50
Started
2015
with 2 others
Phase 2
34 of 114
7 open now
Registered
34th of 114
by date
Lead sponsor
3 of 114
AstraZeneca

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 24th largest by enrollment of the 100 interventional ones that give a count, is one of 3 that started in 2015, is one of 34 in phase 2, and was the 34th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with active proliferative lupus nephritis (LN).

Read the detailed description

This is a Phase 2, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two intravenous (IV) treatment regimens of anifrolumab versus placebo while taking standard of care (SOC) treatment with mycophenolate mofetil (MMF) and corticosteroids in adult subjects with active proliferative lupus nephritis (LN).

03

Conditions studied

  • Lupus Nephritis

Keywords

  • lupus, nephritis, randomized, placebo, anifrolumab, safety, efficacy, adult
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Age 18 through 70 years at the time of screening
  2. Fulfils at least 4 of the 11 criteria of the revised 1982 ACR classification criteria for SLE, at least one of which must be:

    1. Positive antinuclear antibody (ANA) test (1:40 or higher) or
    2. Elevated anti-dsDNA antibodies at screening (reported as equivocal or positive results), as per the centrallaboratory; or
    3. Anti-Smith antibody at screening elevated to above normal (ie, positive or equivocal results) as per the central laboratory
  3. Class III (±Class V) or Class IV (±Class V) LN according to the World Health Organisation (WHO) or 2003 ISN/RPS classification based on a renal obtained within 12 weeks prior to signing the ICF or during the screening period:
  4. Urine protein to creatinine ratio >1 gm/gm (113.17 mg/mmol), obtained on a 24-hour urine collection at screening
  5. Estimated ≥35 mL/min/1.73 m2
  6. Must not have active or latent TB on either chest radiograph or by Quantiferon gold test
  7. Women of must have a negative serum beta-hCG test at screening and negative urine pregnancy test prior to the first dose of sponsor-provided MMF.

Main Exclusion Criteria:

  1. Receipt of any product (small molecule or biologic) or commercially available biologic agent within four weeks or 5 half lives prior to signing of the ICF, whichever is greater
  2. Pure Class V membranous LN on a renal biopsy obtained within 12 weeks prior to signing ICF or during the screening period
  3. Known intolerance to ≤1.0 gm/day of MMF
  4. History of dialysis within 12 months prior to signing the ICF or expected need for renal replacement therapy (dialysis or renal transplant) within a 6 month period after enrolment
  5. Subjects, who at the time of signing the ICF, received any of the following therapies after their qualifying biopsy

    1. Oral >0.5 mg/kg/day for more than 8 weeks or
    2. Oral or IV pulse methylprednisolone >3.0 gm (cumulative dose) or
    3. IV cyclophosphamide >2 pulses of high-dose (≥0.5 gm/m2) or >4 doses of low dose (500 mg every 2 weeks) or
    4. Average MMF >2.5 gm/day (>1800 mg/day of enteric-coated mycophenolate sodium) for more than 8 weeks or
    5. Tacrolimus >4 mg/day for more than 8 weeks
  6. Major surgery within 8 weeks before signing the ICF or major surgery planned during the study period
  7. History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to signing the ICF
  8. Confirmed positive test for or
  9. Any severe herpes infection at any time prior to randomization
  10. Opportunistic infection requiring hospitalisation or parenteral antimicrobial treatment within 3 years prior to randomization (vaginal, oral and skin candidiasis is not an exclusionreason).
  11. History of cancer, apart from:

    1. Squamous or basal cell carcinoma of the skin that has been successfully treated
    2. Cervical cancer in situ that has been successfully treated
  12. Concurrent enrolment in another clinical study with an IP within 4 weeks prior to ICF signing or within 5 half-lives of the IP used in that clinical study, whichever is longer.
  13. During screening (within 30 days before Day 1 [Week 0 visit]), any of the following:

    1. (AST) >2.5× (ULN)
    2. Alanine transaminase (ALT) >2.5×ULN
    3. Total >ULN (unless due to Gilbert's syndrome [based on Investigator's judgement])
    4. Glycosylated () >8% (or >0.08) at screening (diabetic subjects only)
    5. \<1x103/μL (or \<1.0 GI/L)
    6. count \<25x103/μL (or \<25 GI/L)
    7. Haemoglobin \<8 g/dL (or \<80 g/L).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Anifrolumab - Lower Dose

    Anifrolumab - Lower Dose

    Biological: Anifrolumab

  • Experimental
    Anifrolumab - Higher Dose

    Anifrolumab - Higher Dose

    Biological: Anifrolumab

  • Placebo comparator
    Placebo

    Placebo IV Q4W plus SOC

    Drug: Placebo

Interventions

  • BiologicalAnifrolumab

    Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112

  • DrugPlacebo

    Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (UPCR)

    To evaluate the efficacy of anifrolumab plus SOC (combination of mycophenolate mofetil and corticosteroids) compared with placebo plus SOC in subjects with active proliferative lupus nephritis (LN). Geometric mean ratio of 24-hour UPCR at week 52 over baseline. Values \<1 indicate improvement from baseline.

    Time frame: From Week 1 (Baseline) up to Week 52

Secondary outcomes

  1. Proportion of Subjects Achieving the Composite Endpoint Complete Renal Response (CRR)

    CRR was defined as meeting all of the following: * Estimated glomerular filtration rate (eGFR) is ≥60 mL/min/1.73 m\^2 or no confirmed decrease of eGFR from baseline of ≥20% * 24-hour UPCR ≤ 0.7 mg/mg * No discontinuation of investigational product (IP) or use of restricted medication beyond the protocol allowed threshold before assessment * eGFR was based on Modification of Diet in Renal Disease (MDRD) formula. Subjects treated with restricted medication beyond the protocol allowed threshold, or discontinuing study treatment for other reasons, were regarded as non-responders.

    Time frame: Week 52

Other outcomes

  1. Number of Subjects With Adverse Events

    To assess AEs (non-serious, serious and adverse event of special interest (AESI)) as variables of safety and tolerability of anifrolimab. The AESIs are serious infections, including non-opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, TB (including latent TB), influenza, vasculitis (non-SLE), and MACE (including stroke, acute coronary syndrome, myocardial infarction, or cardiovascular death). Study period: During treatment and follow-up data are presented.

    Time frame: From screening (Day-30 to -1) period until the follow-up period (Week 112)

  2. Number of Subjects With Suicidal Ideation and Behavior and Suicide Attempts Via Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS was used to assess the suicidal ideation and behavior and suicide attempts on a graded scale from 1 to 5. 1 indicates as low suicidal and 5 as high suicidal behavior.

    Time frame: Baseline, treatment and follow up (an average of 60 weeks)

  3. Total Score of Personal Health Questionnaire Depression Scale-8 (PHQD-8)

    PHQ-8 is a 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQ-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms.

    Time frame: Baseline, Week 12, Week 24, Week 36, Week 52, Week 60

  4. Extra-renal Flares Using Systemic Lupus Erythematosus (SLE) Disease Activity Index 2000 (SLEDAI 2K) Based Flare Assessment Instrument

    Flare will be defined as any one criterion present in either the Mild/Moderate Flare and/or Severe Flare categories. New or worsened manifestation should only be reported for manifestations of SLE. The SLEDAI-2K score range is 0 to 105 with higher scores representing increased disease activity. Mild/ Moderate flare defined as change in non-renal components of the SLEDAI-2K instrument score of ≥3 but \<7 points compared to previous visit. Severe Flare defined as change in non-renal components of the SLEDAI-2K instrument score by ≥7 points compared to previous visit. The flare rate per subject year is defined as the number of subjects with a respective flare divided by the sum of exposure time in days for all subjects in the analysis set multiplied by 365.25.

    Time frame: From baseline up to week 112

07

Results

Posted Nov 24, 2021

Participant flow

Subjects who met all the inclusion and none of the exclusion criteria were randomized at 66 sites in 16 countries. The study was conducted from 04 November 2015 to 18 January 2021.

Participant flow — Overall Study
MilestoneAnifrolumab - Basic RegimenAnifrolumab - Intensified RegimenPlacebo
Started465249
Fas (full analysis set)455149
Completed182820
Not completed282429
Withdrew: Withdrawal by subject9610
Withdrew: Adverse event312
Withdrew: Lost to follow-up100
Withdrew: Lack of efficacy574
Withdrew: Death100
Withdrew: Non-responding completer, not eligible for extension study, use of any restricted medications489
Withdrew: Technical problems100
Withdrew: Progressive disease102
Withdrew: Physician decision212
Withdrew: Patients did not receive ip110

Outcome measures

PrimaryChange From Baseline in 24-hour Urine Protein to Creatinine Ratio (UPCR)

To evaluate the efficacy of anifrolumab plus SOC (combination of mycophenolate mofetil and corticosteroids) compared with placebo plus SOC in subjects with active proliferative lupus nephritis (LN). Geometric mean ratio of 24-hour UPCR at week 52 over baseline. Values \<1 indicate improvement from baseline.

Time frame:
From Week 1 (Baseline) up to Week 52
Reported as:
Geometric mean · milligram/milligram (mg/mg)
Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (UPCR)
milligram/milligram (mg/mg)Anifrolumab - Basic RegimenAnifrolumab - Intensified RegimenAll AnifrolumabPlacebo
Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (UPCR)0.326 (0.190 to 0.561)0.285 (0.177 to 0.457)0.305 (0.198 to 0.468)0.296 (0.175 to 0.499)
Statistical analysis
  • All Anifrolumab vs Placebo · Mixed Models Analysis · p = 0.9052 (The p-values presented are unadjusted and was compared with the respective adjusted significance level (α). If α is not displayed, no formal testing can be performed and the corresponding p-value was nominal.) · Geometric mean ratio: 1.031 · 95% CI 0.621 to 1.713Geometric mean ratio \>1 favours placebo.
SecondaryProportion of Subjects Achieving the Composite Endpoint Complete Renal Response (CRR)

CRR was defined as meeting all of the following: * Estimated glomerular filtration rate (eGFR) is ≥60 mL/min/1.73 m\^2 or no confirmed decrease of eGFR from baseline of ≥20% * 24-hour UPCR ≤ 0.7 mg/mg * No discontinuation of investigational product (IP) or use of restricted medication beyond the protocol allowed threshold before assessment * eGFR was based on Modification of Diet in Renal Disease (MDRD) formula. Subjects treated with restricted medication beyond the protocol allowed threshold, or discontinuing study treatment for other reasons, were regarded as non-responders.

Time frame:
Week 52
Reported as:
Number · Percentage of subjects
Proportion of Subjects Achieving the Composite Endpoint Complete Renal Response (CRR)
Percentage of subjectsAnifrolumab - Basic RegimenAnifrolumab - Intensified RegimenAll AnifrolumabPlacebo
Responder16.345.531.031.1
Non-responder83.754.569.068.9
Statistical analysis
  • All Anifrolumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.9929 (At Week 52, the p-values presented are unadjusted and will be compared to the respective adjusted significance level (α). If α is not displayed no formal testing can be performed and the corresponding p-value is nominal.) · Difference in estimates: -0.08 · 95% CI -16.92 to 16.76
Other pre-specifiedNumber of Subjects With Adverse Events

To assess AEs (non-serious, serious and adverse event of special interest (AESI)) as variables of safety and tolerability of anifrolimab. The AESIs are serious infections, including non-opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, TB (including latent TB), influenza, vasculitis (non-SLE), and MACE (including stroke, acute coronary syndrome, myocardial infarction, or cardiovascular death). Study period: During treatment and follow-up data are presented.

Time frame:
From screening (Day-30 to -1) period until the follow-up period (Week 112)
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events
ParticipantsAnifrolumab - Basic RegimenAnifrolumab - Intensified RegimenAll AnifrolumabPlacebo
Subjects with any AE- During treatment43479044
Subjects with any acute AE- During treatment11152614
Any AE with outcome of death- During treatment0000
Any SAE (including events with- outcome of death)- During treatment109198
Any AE leading to discontinuation of investigational product- During treatment56115
Any AE related to investigational product (investigator assessment)- During treatment24133716
Any AE of severe intensity- During treatment67138
Any AESI- During treatment1212248
Non-opportunistic serious infections- During treatment0113
Opportunistic infections- During treatment1011
Anaphylaxis- During treatment0000
Malignancy- During treatment0110
Herpes zoster- During treatment97164
Tuberculosis/LTB (latent tuberculosis)- During treatment0000
Influenza- During treatment2461
Vasculitis (non-systemic lupus erythematosus)- During treatment0000
Major adverse cardiovascular events according to the CV-EAC- During treatment0001
Any other significant AE- During treatment0000
Subjects with any AE- follow-up1282022
Any AE with outcome of death- follow-up1010
Any SAE (including events with outcome of death)- follow-up3033
Any AE related to investigational product (investigator assessment)- follow-up2021
Any AE of severe intensity- follow-up2023
Any AESI- follow-up2022
Non-opportunistic serious infections- follow-up0001
Opportunistic infections- follow-up0000
Anaphylaxis- follow-up0000
Malignancy- follow-up0000
Herpes zoster- follow-up2021
Tuberculosis/LTB- follow-up0000
Influenza- follow-up0000
Vasculitis (non-SLE)- follow-up0000
Major adverse cardiovascular events according to the CV-EAC- follow-up0000
Any other significant AE- follow-up0000
Other pre-specifiedNumber of Subjects With Suicidal Ideation and Behavior and Suicide Attempts Via Columbia-Suicide Severity Rating Scale (C-SSRS)

The C-SSRS was used to assess the suicidal ideation and behavior and suicide attempts on a graded scale from 1 to 5. 1 indicates as low suicidal and 5 as high suicidal behavior.

Time frame:
Baseline, treatment and follow up (an average of 60 weeks)
Reported as:
Count of participants · Participants
Number of Subjects With Suicidal Ideation and Behavior and Suicide Attempts Via Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsAnifrolumab - Basic RegimenAnifrolumab - Intensified RegimenAll AnifrolumabPlacebo
Suicidal attempts: Baseline0000
Suicidal attempts: Treatment0000
Suicidal attempts: Follow up0000
Suicidal behaviour: Baseline0000
Suicidal behaviour: Treatment0000
Suicidal behaviour: Follow up0000
Suicidal ideation: Baseline0224
Suicidal ideation: Treatment0002
Suicidal ideation: Follow up0000
Other pre-specifiedTotal Score of Personal Health Questionnaire Depression Scale-8 (PHQD-8)

PHQ-8 is a 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQ-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms.

Time frame:
Baseline, Week 12, Week 24, Week 36, Week 52, Week 60
Reported as:
Mean · Score on a scale
Total Score of Personal Health Questionnaire Depression Scale-8 (PHQD-8)
Score on a scaleAnifrolumab - Basic RegimenAnifrolumab - Intensified RegimenAll AnifrolumabPlacebo
Baseline5.1 ± 4.344.3 ± 4.054.6 ± 4.185.8 ± 4.54
Week 123.4 ± 3.883.1 ± 3.563.2 ± 3.685.1 ± 4.84
Week 242.7 ± 2.412.5 ± 3.182.6 ± 2.864.9 ± 5.10
Week 363.3 ± 4.042.5 ± 3.222.8 ± 3.633.5 ± 2.73
Week 522.3 ± 3.443.4 ± 5.242.9 ± 4.514.2 ± 3.30
Week 603.3 ± 4.805.6 ± 7.014.6 ± 6.064.6 ± 2.07
Other pre-specifiedExtra-renal Flares Using Systemic Lupus Erythematosus (SLE) Disease Activity Index 2000 (SLEDAI 2K) Based Flare Assessment Instrument

Flare will be defined as any one criterion present in either the Mild/Moderate Flare and/or Severe Flare categories. New or worsened manifestation should only be reported for manifestations of SLE. The SLEDAI-2K score range is 0 to 105 with higher scores representing increased disease activity. Mild/ Moderate flare defined as change in non-renal components of the SLEDAI-2K instrument score of ≥3 but \<7 points compared to previous visit. Severe Flare defined as change in non-renal components of the SLEDAI-2K instrument score by ≥7 points compared to previous visit. The flare rate per subject year is defined as the number of subjects with a respective flare divided by the sum of exposure time in days for all subjects in the analysis set multiplied by 365.25.

Time frame:
From baseline up to week 112
Reported as:
Number · Flare rate per subject year
Extra-renal Flares Using Systemic Lupus Erythematosus (SLE) Disease Activity Index 2000 (SLEDAI 2K) Based Flare Assessment Instrument
Flare rate per subject yearAnifrolumab - Basic RegimenAnifrolumab - Intensified RegimenAll AnifrolumabPlacebo
Mild/moderate: All flares0.0190.0160.0170.016
Mild/moderate: On-treatment0.0170.0120.0140.010
Mild/moderate: Off-treatment0.0020.0030.0030.006
Severe: All flares0.0070.0010.0030.006
Severe: On-treatment0.0040.000.0020.004
Severe: Off-treatment0.0030.0010.0020.002

Adverse events

Collected over From screening (Day-30 to -1) period until follow-up (Week 112).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anifrolumab - Basic Regimen- Treatment Period0/45 (0%)10/45 (22.2%)31/45 (68.9%)
Anifrolumab - Intensified Regimen- Treatment Period0/51 (0%)9/51 (17.6%)39/51 (76.5%)
All Anifrolumab- Treatment Period0/96 (0%)19/96 (19.8%)70/96 (72.9%)
Placebo- Treatment Period0/49 (0%)8/49 (16.3%)33/49 (67.3%)
Anifrolumab - Basic Regimen- Follow up1/45 (2.2%)3/45 (6.7%)0/45 (0%)
Anifrolumab - Intensified Regimen- Follow up0/51 (0%)0/51 (0%)0/51 (0%)
All Anifrolumab- Follow up1/96 (1%)3/96 (3.1%)0/96 (0%)
Placebo- Follow up0/49 (0%)3/49 (6.1%)0/49 (0%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventAnifrolumab - Basic Regimen- Treatment PeriodAnifrolumab - Intensified Regimen- Treatment PeriodAll Anifrolumab- Treatment PeriodPlacebo- Treatment PeriodAnifrolumab - Basic Regimen- Follow upAnifrolumab - Intensified Regimen- Follow upAll Anifrolumab- Follow upPlacebo- Follow up
Herpes zosterInfections and infestations3/453/516/960/490/450/510/960/49
InfluenzaInfections and infestations1/451/512/960/490/450/510/960/49
Abscess bacterialInfections and infestations1/450/511/960/490/450/510/960/49
Pyelonephritis acuteInfections and infestations1/450/511/960/490/450/510/960/49
Lupus endocarditisCardiac disorders1/450/511/960/490/450/510/960/49
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders1/450/511/960/490/450/510/960/49
Lupus nephritisRenal and urinary disorders1/451/512/961/491/450/511/960/49
MalaiseGeneral disorders1/450/511/960/490/450/510/960/49
Infusion related reactionInjury, poisoning and procedural complications1/450/511/960/490/450/510/960/49
HypoaesthesiaNervous system disorders0/450/510/960/491/450/511/960/49
Most frequent other events
Showing 10 of 21
Most frequent other events
EventAnifrolumab - Basic Regimen- Treatment PeriodAnifrolumab - Intensified Regimen- Treatment PeriodAll Anifrolumab- Treatment PeriodPlacebo- Treatment PeriodAnifrolumab - Basic Regimen- Follow upAnifrolumab - Intensified Regimen- Follow upAll Anifrolumab- Follow upPlacebo- Follow up
Urinary tract infectionInfections and infestations10/456/5116/965/490/450/510/960/49
DiarrhoeaGastrointestinal disorders3/454/517/9610/490/450/510/960/49
NasopharyngitisInfections and infestations6/459/5115/969/490/450/510/960/49
Upper respiratory tract infectionInfections and infestations8/457/5115/968/490/450/510/960/49
BronchitisInfections and infestations4/457/5111/966/490/450/510/960/49
Herpes zosterInfections and infestations6/454/5110/964/490/450/510/960/49
CoughRespiratory, thoracic and mediastinal disorders4/453/517/964/490/450/510/960/49
HeadacheNervous system disorders2/453/515/964/490/450/510/960/49
DyspepsiaGastrointestinal disorders2/450/512/964/490/450/510/960/49
VomitingGastrointestinal disorders1/451/512/964/490/450/510/960/49

Baseline characteristics

The full analysis set included all subjects who received at least one dose of study treatment and were analyzed according to randomized treatment.

Age, Continuous
Age, Continuous(years)Anifrolumab - Basic RegimenAnifrolumab - Intensified RegimenPlaceboTotal
Mean35.2 ± 11.4935.0 ± 10.5834.0 ± 10.1834.7 ± 10.68
Sex: Female, Male
Sex: Female, Male(Participants)Anifrolumab - Basic RegimenAnifrolumab - Intensified RegimenPlaceboTotal
Female374538120
Male861125
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Anifrolumab - Basic RegimenAnifrolumab - Intensified RegimenPlaceboTotal
Hispanic or Latino22232065
Not Hispanic or Latino23282980
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Anifrolumab - Basic RegimenAnifrolumab - Intensified RegimenPlaceboTotal
American Indian or Alaska Native3104
Asian1171028
Native Hawaiian or Other Pacific Islander1001
Black or African American2417
White17252466
Other11141439
08

Study locations

80 sites
  • Research Site
    Glendale, Arizona 85306, United States
  • Research Site
    Phoenix, Arizona 85032, United States
  • Research Site
    La Jolla, California 92037-0706, United States
  • Research Site
    Los Angeles, California 90095-1670, United States
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    DeBary, Florida 32713, United States
  • Research Site
    Boston, Massachusetts 02118, United States
  • Research Site
    Newark, New Jersey 07103-2499, United States
  • Research Site
    Bronx, New York 10457, United States
  • Research Site
    Great Neck, New York 11021, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Buenos Aires, C1015ABO, Argentina
  • Research Site
    Cordoba, 5016, Argentina
  • Research Site
    Rosario, S2000PBJ, Argentina
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Clayton, VIC 3168, Australia
  • Research Site
    Parkville, 3050, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Brussels, 1070, Belgium
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liege, B-4000, Belgium
  • Research Site
    Bordeaux Cedex, 33076, France
  • Research Site
    Marseille, 13005, France
  • Research Site
    Paris Cedex 14, 75013, France
  • Research Site
    Strasbourg, 67098, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Kiel, 24105, Germany
  • Research Site
    Budapest, 1097, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Kaposvár, 7400, Hungary
  • Research Site
    Szeged, 6725, Hungary
  • Research Site
    Milano, 20132, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Pisa, 56126, Italy
  • Research Site
    Reggio Emilia, 42100, Italy
  • Research Site
    Gwangju, 501-757, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Seoul, 150-713, Korea, Republic of
  • Research Site
    Suwon-si, 16499, Korea, Republic of
  • Research Site
    Chihuahua, 31000, Mexico
  • Research Site
    Guadalajara, 44160, Mexico
  • Research Site
    Guadalajara, 44280, Mexico
  • Research Site
    Mexico, 14080, Mexico
  • Research Site
    San Luis Potosí, 78213, Mexico
  • Research Site
    Arequipa, AREQUIPA54, Peru
  • Research Site
    Lima, L14, Peru
  • Research Site
    Lima, L34, Peru
  • Research Site
    Lima, LIMA 01, Peru
  • Research Site
    Lima, LIMA 31, Peru
  • Research Site
    Lima, LIMA 32, Peru
  • Research Site
    Lima, LIMA 33, Peru
  • Research Site
    Lima, Lima-1, Peru
  • Research Site
    Lima, Peru
  • Research Site
    Krakow, 31-066, Poland
  • Research Site
    Warszawa, 02-637, Poland
  • Research Site
    Łódź, 92-213, Poland
  • Research Site
    Orenburg, 460018, Russian Federation
  • Research Site
    Saint Petersburg, 197022, Russian Federation
  • Research Site
    Saint Petersburg, 197089, Russian Federation
  • Research Site
    Belgrade, 11000, Serbia
  • Research Site
    Belgrade, 1100, Serbia
  • Research Site
    Nis, 18000, Serbia
  • Research Site
    Novi Sad, 21000, Serbia
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Changhua City, 50006, Taiwan
  • Research Site
    Kaohsiung, 80756, Taiwan
  • Research Site
    Taichung, 40447, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Taipei, 100, Taiwan
  • Research Site
    Taoyuan City, 333, Taiwan
  • Research Site
    London, E1 1BB, United Kingdom
09

References and documents

Publications

  • Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, Knagenhjelm J, Schwetje E, Chia YL, Tummala R, Lindholm C. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022 Apr;81(4):496-506. doi: 10.1136/annrheumdis-2021-221478. Epub 2022 Feb 10. PubMed 35144924 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Nov 2019, 48 months.

Results were first posted in Nov 2021, 1 year 11 months after primary completion. A results delay was requested in Sep 2020.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2015
First posted
Sep 14, 2015
StartActual
Nov 4, 2015
Primary completionActual
Nov 26, 2019
CompletionActual
Jan 18, 2021
Results delay requested
Sep 14, 2020
Results first posted
Nov 24, 2021
Last update
Nov 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02547922
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Sep 14, 2015
Start date
Nov 4, 2015
Primary completion
Nov 26, 2019
Completion
Jan 18, 2021
Results posted
Nov 24, 2021
Last update
Nov 24, 2021

Study contacts

AstraZeneca AB
study director · AstraZeneca

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion